Metastatic Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Conditions
Brief summary
This phase I/II trial tests the safety and effectiveness of cell therapy (STEAP1 CART) with enzalutamide in treating patients with prostate cancer that continues to grow despite surgical or medical treatments to block androgen production (castration-resistant) and that has spread from where it first started (the prostate) to other places in the body (metastatic). Prostate cancer is the second leading cause of cancer deaths in men. Localized prostate cancer is often curable and even metastatic disease may respond to treatment for a few years. Despite multiple therapies, including hormone therapy and chemotherapy, metastatic castration-resistant prostate cancer (mCRPC) remains an incurable disease. Recently, adoptive cellular immunotherapies have been developed to transfer immunogenic cells to the patient to produce an anti-tumor response. Chimeric antigen receptor T (CART)-cell therapy is a type of treatment in which a patient's T-cells (a type of immune cell) are changed in the laboratory so they will attack tumor cells. T cells are taken from a patient's blood. Then the gene for a special receptor that binds to a certain protein on the patient's tumor cells is added to the T cells in the laboratory. The special receptor is called a chimeric antigen receptor (CAR). Large numbers of the CAR T cells are grown in the laboratory and given to the patient by infusion for treatment of certain cancers. Prostate stem cell antigen and prostate specific membrane antigen CAR T cell therapies have been shown to be safe and effective, but objective tumor responses remain rare. STEAP1 is an antigen that promotes cancer growth and spread and is found to be broadly expressed in mCRPC tissues. STEAP1 CART is CAR T cells that have been engineered with a STEAP1 antigen to better target prostate tumor cells. Enzalutamide is in a class of medications called androgen receptor inhibitors. It works by blocking the effects of androgen (a male reproductive hormone) to stop the growth and spread of cancer cells. Giving STEAP1 CART with enzalutamide may kill more tumor cells in patients with mCRPC.
Detailed description
OUTLINE: This is a dose escalation study of STEAP1 CART in combination with enzalutamide followed by a dose expansion study. Patients undergo leukapheresis then receive cyclophosphamide intravenously (IV) and fludarabine IV on days -5, -4 and -3 and STEAP1 CART IV on day 0. Patients may receive enzalutamide orally (PO) on day 0 then once daily (QD) in the absence of disease progression or unacceptable toxicity. Patients also undergo a tumor biopsy at baseline, day 14 and optionally at progression. Patients additionally undergo blood sample collection, nuclear medicine (NM) bone scan and computed tomography (CT) scan, or magnetic resonance imaging (MRI) or positron emission tomography (PET) scan throughout study. Additionally, patients may undergo echocardiography (ECHO) or multigated acquisition scan (MUGA) at screening. After completion of study treatment, patients are followed up at 2, 3, 4, 5, 6, 9, and 12 months then every 6 months up to year 5 followed by yearly up to year 15.
Interventions
BIOLOGICALAnti-STEAP1 CAR T-cells
Given IV
PROCEDUREBiopsy Procedure
Undergo tumor biopsy
PROCEDUREBiospecimen Collection
Undergo blood sample collection
PROCEDUREBone Scan
Undergo NM bone scan
PROCEDUREComputed Tomography
Undergo CT scan
DRUGCyclophosphamide
Given IV
PROCEDUREEchocardiography Test
Undergo ECHO
DRUGEnzalutamide
Given PO
DRUGFludarabine
Given IV
PROCEDURELeukapheresis
Undergo leukapheresis
PROCEDUREMagnetic Resonance Imaging
Undergo MRI
PROCEDUREMultigated Acquisition Scan
Undergo MUGA
PROCEDUREPositron Emission Tomography
Undergo PET scan
Sponsors
Fred Hutchinson Cancer Center
PromiCell Therapeutics, Inc.
National Cancer Institute (NCI)
Study design
Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Tissue confirmation of prostate adenocarcinoma * Measurable disease by RECIST 1.1 criteria or bone only metastases with measurable PSA ( ≥ 1 ng/mL) * Must have progressed (at least 2 rising PSA levels with at least a 1-week interval and a minimum PSA of 1.0 ng/mL, progression per RECIST 1.1, or 2 or more new bone lesions by bone scan), after becoming castration-resistant * Have received the following for metastatic prostate cancer: * At least two lines of treatment * At least two Food and Drug Administration (FDA)-approved therapies with at least one being a second generation androgen receptor signaling inhibitor (e.g., abiraterone, darolutamide, apalutamide, or enzalutamide) * All available targeted therapies for which they are eligible in the metastatic setting (e.g., PARP inhibitors for BRCA 1/2 and immune checkpoint inhibitor for MSI-H or TMB-H ≥ 10 mut/Mb) * Castrate levels of testosterone (\< 50 ng/dL) with or without the use of androgen deprivation therapy (ADT) * 18 years or older at the time of enrollment * Capable of understanding and providing a written informed consent * Fertile male participants and their female partners must be willing to use an effective contraceptive method before, during, and for at least 4 months after the STEAP1 CART cell infusion * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Participants will be permitted to receive radiation therapy for palliative purposes throughout the study period, except during the 2-week period prior to undergoing leukapheresis * Serum creatinine =\< 1.5 x upper limit of normal (ULN) or estimated creatinine clearance \> 50 mL/min as calculated using the Cockcroft-Gault formula and not dialysis dependent * Total bilirubin ≤ 1.5 x ULN. Participants with suspected Gilbert syndrome may be included if Total bilirubin (Bili) \> 3 mg/dL but no other evidence of hepatic dysfunction * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \< 5 x ULN * ≤ grade 1 dyspnea and oxygen saturation (SaO2) ≥ 92% on ambient air * If pulmonary function tests (PFTs) are performed based on the clinical judgement of the treating physician, participants with forced expiratory volume in 1 second (FEVI) \>= 50% of predicted and diffusion capacity of the lung for carbon monoxide (DLCO) (corrected) of \>= 40% of predicted will be eligible * Participants \>= 60 years of age are required to have left ventricular ejection fraction (LVEF) evaluation performed within 1 year prior to lymphodepletion chemotherapy. LVEF may be established with echocardiogram or MUGA scan, and left ejection fraction must be \>= 35%. Cardiac evaluation for other participants is at the discretion of the treating physician * Absolute neutrophil count (ANC) \> 1500 cells/ mm\^3 * Hemoglobin \>= 9 g/dL * Platelets \> 100,000 per mm\^3
Exclusion criteria
* Expecting to conceive or father children for the duration of the trial through 4 months after T cell infusion * Active autoimmune disease: Participants with active autoimmune disease requiring immunosuppressive therapy are excluded. Case by case exemptions are possible with approval by principal investigator (PI) * Corticosteroid therapy at a dose equivalent of \>15 mg of prednisone per day (or equivalent). Pulsed corticosteroid use for disease control is acceptable * Concurrent use of other investigational anti-cancer agents except for ADT * Active uncontrolled infection: human immunodeficiency virus (HIV) positive participants on highly active antiretroviral therapy (HAART) with a CD4 count \> 500 cells/mm\^3 are considered controlled, as are individuals with a history of hepatitis C who have successfully completed antiviral therapy with an undetectable viral load, and those with hepatitis B who have hepatitis well controlled on medication * Uncontrolled concurrent illness: Participants may not have uncontrolled or concurrent illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia that would limit compliance with study requirements * Participants with brain metastasis * Active treatment for prior immune related adverse event to any immunotherapy: Participants receiving ongoing treatment for prior serious immune-related adverse events are excluded, with exception of hormone supplementation or corticosteroid therapy at equivalent of \> 15 mg prednisone (or equivalent) per day, unless otherwise approved by PI * Significant underlying neurologic disease: Study participants must not have significant active underlying neurologic disease, unless approved by PI. Peripheral neuropathy related to diabetes or prior chemotherapy is acceptable * Other medical, social, or psychiatric factor that interferes with medical appropriateness and/or ability to comply with study, as determined by the PI * Known allergic reactions to any of the components of study treatments * Participants with no bridging therapy options according to the treating medical oncologist. The specific bridging treatment plan must be documented in the Electronic Medical Record (EMR) by the treating medical oncologist within 2 weeks of signing informed consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of grade 3 or higher treatment related unexpected adverse events (AEs) (Phase I) | Up to 28 days post infusion | Toxicity will be graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version (v) 5.0. |
| Incidence of AEs (Phase II) | Up to 28 days post infusion | Toxicity will be graded according to NCI CTCAE v 5.0. |
| Response (Phase II) | Up to 1 year post infusion | Response will be defined as best overall response rate by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and/or Prostate Cancer Working Group 3 (PCWG3) criteria. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression free survival (PFS) | At time from initiation of protocol treatment to disease progression or death up to 1 year post infusion | PFS will be estimated using the method of Kaplan and Meier with time zero being the time of first T cell infusion. |
| Frequency of participants that achieve an overall response rate (ORR, including complete and partial response) according to RECIST v.1.1 or PCWG3 | Anti-tumor response according to RECIST v1.1 or PCWG3 up to 1 year post infusion | To measure how well the treatment succeeds in producing the desired effect. |
| ORR by immune RECIST | Up to 1 year post infusion | — |
| Frequency of participants that achieve a stable disease (SD) according to RECIST v.1.1 or PCWG3 | Anti-tumor response according to RECIST v1.1 or PCWG3 up to 1 year post infusion | To measure how well the treatment succeeds in producing the desired effect. |
| Frequency of participants that achieve a clinical benefit rate (ORR + SD) stable disease RECIST v.1.1 or PCWG3 | Anti-tumor response according to RECIST v1.1 or PCWG3 up to 1 year post infusion | To measure how well the treatment succeeds in producing the desired effect. |
| Overall survival (OS) | At time from initiation of protocol treatment to death of any cause up to 1 year post infusion | OS will be estimated using the method of Kaplan and Meier with time zero being the time of first T cell infusion. |
| Prostate specific antigen (PSA) response | At baseline up to 1 year post infusion | PSA responses, defined as \>= 50% reductions in PSA from baseline at any point post baseline assessment will be calculated. |
| Time to response (TTR) | At time from study infusion to time of first documented response up to 1 year post infusion | TTR will be assessed from the time of study infusion to time of first documented response (partial response \[PR\] or better). |
| Duration of response (DOR) | At time of first documented response to time of confirmed progression up to 1 year post infusion | DOR will be assessed from the time of first documented response (PR or better) to time of confirmed disease progression. |
Countries
United States
Contacts
CONTACTFred Hutch Intake
PRINCIPAL_INVESTIGATORRosa Nadal Rios, MD, PhD
Fred Hutch/University of Washington Cancer Consortium
Outcome results
None listed